How to Use Rusfertide

Complete guide to Rusfertide dosing, administration, timing, and protocol recommendations.

Quick Overview

Rusfertide is an injectable peptide that mimics hepcidin, the body's master hormone for controlling iron, and it is being developed to manage polycythemia vera (PV), a blood cancer that makes too many red blood cells. By limiting iron availability, it throttles red blood cell production and reduces the need for repeated blood draws (phlebotomy). It is a late-stage investigational drug, not a research-only or gray-market peptide: it cleared a positive phase 3 trial and is under FDA priority review.

Dosing Guidelines

Common Dose

40-80 mg weekly

Frequency

Once weekly

Dose Range

10-120 mg weekly (trial range)

Note: Dose titrated based on hematocrit response. In REVIVE trial, most patients stabilized at 40-80 mg weekly. Designed as chronic therapy. Being studied primarily for polycythemia vera but has potential application for TRT-induced erythrocytosis (elevated hematocrit from testosterone therapy).

Administration Method

Subcutaneous injection, once weekly

Best Time to Take

Once weekly, consistent day

Long-acting hepcidin mimetic with weekly dosing schedule. Designed for once-weekly subcutaneous injection for convenience and compliance.

Protocol Duration

Ongoing - designed for chronic use

Possible Side Effects

Not everyone experiences these. Individual responses vary.

  • Injection site reactions (most common, mild)
  • Iron deficiency (expected mechanism of action)
  • Fatigue
  • Dizziness
  • Headache

Frequently Asked Questions

What is the recommended dose for Rusfertide?

40-80 mg weekly

How do you administer Rusfertide?

Subcutaneous injection, once weekly

When is the best time to take Rusfertide?

Once weekly, consistent day

How long should you use Rusfertide?

Ongoing - designed for chronic use

This information is for educational purposes only. Always consult with a healthcare professional before using any peptide. Dosing information is based on research literature and community reports, not medical advice.